Literature DB >> 290351

Development of resistance to amphotericin B in Candida lusitaniae infecting a human.

D Pappagianis, M S Collins, R Hector, J Remington.   

Abstract

Candida lusitaniae associated with infection in a patient with acute myelogenous leukemia developed resistance to amphotericin B during systemic treatment of the patient. The organism, when isolated initially, was inhibited by 0.31 mug of amphotericin B per ml in yeast nitrogen base agar, but when isolated (20 days later) just antemortem and postmortem, required 100 and 50 mug/ml, respectively, for complete inhibition at 48 h.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 290351      PMCID： PMC352808          DOI： 10.1128/AAC.16.2.123

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Inhibition of growth of Coccidioides immitis on Sabouraud medium containing polymyxin B.

Authors:  M S Collins
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

Review 2.  Fungal sterols and the mode of action of the polyene antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Adv Appl Microbiol       Date:  1974       Impact factor: 5.086

3.  Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria.

Authors:  R A Woods; M Bard; I E Jackson; D J Drutz
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

4.  Resistance studies of Candida albicans, with special reference to two patients subjected to prolonged antimycotic treatment.

Authors:  J Bodenhoff
Journal:  Odontol Tidskr       Date:  1968-06-28

5.  Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis.

Authors:  L M Safe; S H Safe; R E Subden; D C Morris
Journal:  Can J Microbiol       Date:  1977-04       Impact factor: 2.419

Review 6.  Opportunistic fungal infections in patients with neoplastic diseases.

Authors:  P P Rosen
Journal:  Pathol Annu       Date:  1976

7.  Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function.

Authors:  D J Drutz; R I Lehrer
Journal:  Am J Med Sci       Date:  1978 Jul-Aug       Impact factor: 2.378

8.  Identification of Candida lusitaniae as an opportunistic yeast in humans.

Authors:  D L Holzschu; H L Presley; M Miranda; H J Phaff
Journal:  J Clin Microbiol       Date:  1979-08       Impact factor: 5.948

9.  Factors influencing experimental candidiasis in mice. I. Alloxan diabetes.

Authors:  V T ANDRIOLE; H F HASENCLEVER
Journal:  Yale J Biol Med       Date:  1962-08
  10 in total
  56 in total

1.  Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.

Authors:  C J Clancy; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.

Authors:  B A Arthington-Skaggs; M Motley; D W Warnock; C J Morrison
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 3.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 4.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

5.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 6.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  Candida lusitaniae causing fatal meningitis.

Authors:  P S Sarma; P Durairaj; A A Padhye
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

8.  In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole.

Authors:  D G Ahearn; M S McGlohn
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

9.  Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae.

Authors:  Laura Y Young; Christina M Hull; Joseph Heitman
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Identification of Candida lusitaniae as an opportunistic yeast in humans.

Authors:  D L Holzschu; H L Presley; M Miranda; H J Phaff
Journal:  J Clin Microbiol       Date:  1979-08       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.